Cargando…

Developing SHP2-based combination therapy for KRAS-amplified cancer

Gastroesophageal adenocarcinomas (GEAs) harbor recurrent amplification of KRAS, leading to marked overexpression of WT KRAS protein. We previously demonstrated that SHP2 phosphatase, which acts to promote KRAS and downstream MAPK pathway activation, is a target in these tumors when combined with MEK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tianxia, Kikuchi, Osamu, Zhou, Jin, Wang, Yichen, Pokharel, Babita, Bastl, Klavdija, Gokhale, Prafulla, Knott, Aine, Zhang, Yanxi, Doench, John G., Ho, Zandra V., Catenacci, Daniel V.T., Bass, Adam J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977440/ https://www.ncbi.nlm.nih.gov/pubmed/36752207 http://dx.doi.org/10.1172/jci.insight.152714

Ejemplares similares

Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2
por: Wong, Gabrielle S., et al.
Publicado: (2018)

Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
por: Catenacci, Daniel V.T.
Publicado: (2014)

Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care
por: Sehdev, Amikar, et al.
Publicado: (2013)

SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development
por: Gagné-Sansfaçon, Jessica, et al.
Publicado: (2016)

SHP2 inhibition diminishes KRAS(G12C) cycling and promotes tumor microenvironment remodeling
por: Fedele, Carmine, et al.
Publicado: (2020)

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
por: Franciosa, Giulia, et al.
Publicado: (2023)

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
por: Gebregiworgis, Teklab, et al.
Publicado: (2021)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2–Induced Gastrulation Defects
por: Jopling, Chris, et al.
Publicado: (2007)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Functions of Shp2 in cancer
por: Zhang, Jie, et al.
Publicado: (2015)

Sidestepping SHP2 inhibition
por: Popescu, Bogdan, et al.
Publicado: (2023)

Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
por: Xu, Xiaozheng, et al.
Publicado: (2021)

Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization
por: Buck, Sara J. S., et al.
Publicado: (2022)

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
por: Taylor, Julia, et al.
Publicado: (2023)

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma
por: Ananthapadmanabhan, Varsha, et al.
Publicado: (2022)

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
por: Nardi, Francesca, et al.
Publicado: (2023)

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD–Driven AML
por: Pfeiffer, Anamarija, et al.
Publicado: (2022)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown
por: Srikar, R., et al.
Publicado: (2016)

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer
por: Feng, Hui‐Bo, et al.
Publicado: (2021)

Wild-type blocking pcr coupled with internal competitive amplified fragment improved the detection of rare mutation of KRAS
por: Peng, Jia, et al.
Publicado: (2017)

Intestinal transit amplifying cells require METTL3 for growth factor signaling, KRAS expression, and cell survival
por: Danan, Charles H., et al.
Publicado: (2023)

Skeletal malformation and the SHP-2 pathway
Publicado: (2011)

Shp1 in Solid Cancers and Their Therapy
por: Varone, Alessia, et al.
Publicado: (2020)

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
por: Xu, Xiaozheng, et al.
Publicado: (2020)

Intraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect
por: Sun, Ziying, et al.
Publicado: (2022)

Destabilization of the SHP2 and SHP1 protein tyrosine phosphatase domains by a non-conserved “backdoor” cysteine
por: Yarnall, Matthew T.N., et al.
Publicado: (2022)

Protein-protein interaction between caveolin-1 and SHP-2 is dependent on the N-SH2 domain of SHP-2
por: Park, Hyunju, et al.
Publicado: (2015)

Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis
por: Zhao, Hua, et al.
Publicado: (2018)

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

ROCKs cause SHP-wrecks and broken hearts
por: Tandon, Panna, et al.
Publicado: (2012)

Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
por: Patsoukis, Nikolaos, et al.
Publicado: (2020)

Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation
por: Sha, Fern, et al.
Publicado: (2023)

shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells
por: Subrakova, V.G., et al.
Publicado: (2020)

ahctf1 and kras mutations combine to amplify oncogenic stress and restrict liver overgrowth in a zebrafish model of hepatocellular carcinoma
por: Morgan, Kimberly J, et al.
Publicado: (2023)

Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling
por: Choi, Eunhee, et al.
Publicado: (2019)

SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia
por: Pérez-Fernández, Alejandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_82511nemgn30fmasbgj8svd5hu